Physician profile
John Max Deloach
NPI 1740252873
$4,959.56
in general payments reported to CMS, 2019-2025
24 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $266 · 2021: $324 · 2022: $2,161 · 2023: $694 · 2024: $213 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $1,934.43 | 2021-2022 | |
| Endologix LLC | $1,074.45 | 2019-2025 | Afx2 Bifurcated Endograft System, Ovation Ix Iliac Stent Graft |
| Ethicon US, LLC | $1,042.92 | 2019-2025 | Echelon; Endopath, Echelon Endopath, Vistaseal |
| Medtronic, INC. | $212.37 | 2021-2023 | Endurant Iis, In.Pact Av |
| Vertex Pharmaceuticals Incorporated | $91.32 | 2024-2025 | |
| Innocoll Pharmaceuticals Limited | $77.55 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $75.66 | 2022-2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Smith+Nephew, INC. | $51.61 | 2019-2021 | |
| Heron Therapeutics, INC. | $49.38 | 2025 | Zynrelef |
| Kci USA, INC. | $47.60 | 2019-2021 | |
| Solventum Corporation | $40.41 | 2024-2025 | V.A.C. Veraflo Cleanse Choice, Prevena, Abthera Advance |
| Davol INC. | $40.07 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.76 | 2021 | |
| Merz Pharmaceuticals, LLC | $29.02 | 2024 | Xeomin |
| Kowa Pharmaceuticals America, INC. | $27.94 | 2022-2023 | Seglentis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $20.52 | 2025 | Irrisept |
| Medline Industries LP | $18.08 | 2020 | |
| Medtronic Vascular, INC. | $17.23 | 2020 | |
| Elutia, INC. | $13.29 | 2019 | |
| Acera Surgical, INC. | $12.84 | 2019 | |
| Kerecis Limited | $12.57 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Bolder Surgical, LLC | $11.97 | 2022 | |
| Baudax Bio INC. | $11.95 | 2020 | |
| Bolder Surgical LLC | $8.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Deloach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.